In addition, we analysed the mRNA and protein expression of ARID1A in different subtypes of breast cancer and found that ARID1A levels in the luminal and HER2-positive subtypes were higher than those observed in TNBC (as demonstrated in Figure 1F). This evidence concerns the gene ERBB2 and breast carcinoma.